Suzanne L Topalian
Overview
Explore the profile of Suzanne L Topalian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
35757
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeng Z, Zhang T, Zhang J, Li S, Connor S, Zhang B, et al.
Nat Commun
. 2025 Feb;
16(1):1070.
PMID: 39900903
Identifying tumor-specific T cell clones that mediate immunotherapy responses remains challenging. Mutation-associated neoantigen (MANA) -specific CD8+ tumor-infiltrating lymphocytes (TIL) have been shown to express high levels of CXCL13 and CD39...
2.
Bhatia S, Topalian S, Sharfman W, Meyer T, Steven N, Lao C, et al.
J Clin Oncol
. 2025 Jan;
43(9):1137-1147.
PMID: 39889250
Purpose: Approximately 50% of patients with advanced Merkel cell carcinoma (MCC) have primary or acquired resistance to PD-(L)1 blockade, which may be overcome using combination immune checkpoint inhibition (ICI) with...
3.
Topalian S, Pardoll D
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39855712
Neoadjuvant (presurgical) anti-programmed cell death protein-1 (PD-1)-based immunotherapy as a new approach to cancer treatment has been developing on an accelerated trajectory since the seminal clinical trial results from studies...
4.
McMiller T, Besharati S, Yarchoan M, Zhu Q, Unsal-Kacmaz K, Xu K, et al.
J Immunother Cancer
. 2024 Nov;
12(11.
PMID: 39572160
Background: Gastric carcinomas (GC) are aggressive malignancies, and only ~15% of patients respond to anti-programmed cell death (ligand) 1 (PD-(L)1) monotherapy. However, Epstein-Barr virus (EBV)-associated GCs (~5-10% of GCs) often...
5.
Long G, Larkin J, Schadendorf D, Grob J, Lao C, Marquez-Rodas I, et al.
J Clin Oncol
. 2024 Nov;
43(8):938-948.
PMID: 39504507
Purpose: Nivolumab (NIVO) + ipilimumab (IPI) combination and NIVO monotherapy have demonstrated durable clinical benefit in patients with unresectable/metastatic melanoma. This analysis describes long-term overall survival (OS) with the combination...
6.
Hansen U, Church C, Carnaz Simoes A, Frej M, Bentzen A, Tvingsholm S, et al.
J Clin Invest
. 2024 Apr;
134(8).
PMID: 38618958
Merkel cell carcinoma (MCC) is a highly immunogenic skin cancer primarily induced by Merkel cell polyomavirus, which is driven by the expression of the oncogenic T antigens (T-Ags). Blockade of...
7.
Oaknin A, Moore K, Meyer T, Lopez-Picazo Gonzalez J, Devriese L, Amin A, et al.
Lancet Oncol
. 2024 Apr;
25(5):588-602.
PMID: 38608691
Background: In preliminary findings from the recurrent or metastatic cervical cancer cohort of CheckMate 358, nivolumab showed durable anti-tumour responses, and the combination of nivolumab plus ipilimumab showed promising clinical...
8.
Chen S, McMiller T, Soni A, Succaria F, Sidhom J, Cappelli L, et al.
J Transl Med
. 2024 Mar;
22(1):241.
PMID: 38443917
Background: Tumor regression following immune checkpoint blockade (ICB) is often associated with immune-related adverse events (irAEs), marked by inflammation in non-cancerous tissues. This study was undertaken to investigate the functional...
9.
Pulliam T, Jani S, Jing L, Ryu H, Jojic A, Shasha C, et al.
Cell Rep Med
. 2024 Feb;
5(2):101412.
PMID: 38340723
Understanding cancer immunobiology has been hampered by difficulty identifying cancer-specific T cells. Merkel cell polyomavirus (MCPyV) causes most Merkel cell carcinomas (MCCs). All patients with virus-driven MCC express MCPyV oncoproteins,...
10.
Schenk K, Deutsch J, Chandra S, Davar D, Eroglu Z, Khushalani N, et al.
J Clin Oncol
. 2024 Jan;
42(9):1011-1020.
PMID: 38252910
Purpose: Cancer-related mortality rates among kidney transplant recipients (KTR) are high, but these patients have largely been excluded from trials of immune checkpoint inhibitors because of immunosuppression and risk of...